Drug Shortage Report for MOXIFLOXACIN INJECTION
| Report ID | 224325 |
| Drug Identification Number | 02433087 |
| Brand name | MOXIFLOXACIN INJECTION |
| Common or Proper name | MOXIFLOXACIN INJECTION |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | MOXIFLOXACIN |
| Strength(s) | 400MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 250 mL |
| ATC code | J01MA |
| ATC description | QUINOLONE ANTIBACTERIALS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2024-05-01 |
| Actual start date | |
| Estimated end date | 2024-07-08 |
| Actual end date | |
| Shortage status | Anticipated shortage |
| Updated date | 2024-04-04 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Moxifloxacin Injection 1.6 mg/mL freeflex® Bag 250 mL effective May 1, 2024, until July 8, 2024. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2024-04-04 | French | Compare |
| v1 | 2024-04-04 | English | Compare |
Showing 1 to 2 of 2